Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, December 22 2014 4:20am ET - U.S. Markets open in 5 hours and 10 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Biotechnology News
Latest News
Monday, Dec 22, 2014
·BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza
GlobeNewswire - 25 minutes ago
·New Published Data Show Pluristem's PLX Cells Protect Neurons
GlobeNewswire - 1 hour, 20 minutes ago
·PEH's Portfolio Company Enanta announces U.S. FDA Approval for AbbVie's VIEKIRA PAK(TM)
Thomson Reuters ONE - Mon 1:04 am ET
Friday, Dec 19, 2014
·U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks
Reuters - Fri Dec 19
·[$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa
at The Wall Street Journal Online - Fri Dec 19
·AbbVie says newly approved hepatitis C treatment costs $83,319
Reuters - Fri Dec 19
·Final Glance: Biotechnology companies
AP - Fri Dec 19
·FDA Approves Second Cubist Antibiotic Of 2014
at Forbes.com - Fri Dec 19
·Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
Business Wire - Fri Dec 19
·FDA approves Cubists' drug for antibiotic-resistant bacteria
Reuters - Fri Dec 19
·Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
Business Wire - Fri Dec 19
·Update on CMS Reimbursement for Cologuard®
Business Wire - Fri Dec 19
·AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead?
at Barrons.com - Fri Dec 19
·SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna Zentaris, Inc. and Certain Officers - AEZS
PR Newswire - Fri Dec 19
·US STOCKS-Wall St up for 3rd day, led by energy shares
Reuters - Fri Dec 19
·Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next
at TheStreet.com - Fri Dec 19
·Advaxis Completes $17 Million Financing
GlobeNewswire - Fri Dec 19
·FDA approves AbbVie’s hepatitis treatment
at MarketWatch - Fri Dec 19
·Exact Sciences Addresses CMS Reimbursement for Cologuard®
Business Wire - Fri Dec 19
·US STOCKS-Wall St adds gains in late trade; energy leads
Reuters - Fri Dec 19
More Latest News...
Sponsor Results
Biotechnology News
Tips to Evaluate Cloud Service Providers. Ask the Right Questions.
TechTarget.com
Business Services
Find Business Services In Your Area With Local.com!
Local.com
Shimadzu Life Science
A new way of thinking in the health and life science industries
www.ssi.shimadzu.com
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?